JUL 31, 2019 6:30 PM PDT

Ketamine is not an opioid, and treats depression in a novel way

In March, the U.S. Food and Drug Administration approved ketamine nasal spray to treat depression. Ketamine has gotten a bad rap as an opioid - which it is not - despite solid scientific evidence suggesting that it isn't one.

According to Adam Kaplin, M.D., Ph.D., an assistant professor of psychiatry and behavioral sciences at Johns Hopkins School of Medicine, both patients and physicians tend to perceive ketamine as an opioid. "This is most worrisome if people continue to think this way, particularly in the wake of the opioid epidemic; clinicians won't refer patients for treatment, despite that it has been shown to be incredibly effective for many patients with treatment-resistant depression," says Kaplin.

Researchers published their viewpoint and explanation of the drug's mechanism as a Letter to the Editor in the American Journal of Psychiatry

Naltrexone - a drug used to treat opioid addiction by preventing opioid effects (e.g. feelings of well-being, pain relief) - binds to opioid receptors on brain cells and prevents other opioids like heroin from binding. In 2018, a study showed that naltrexone also blocks the antidepressant effects of ketamine, which led researchers to conclude that ketamine may also bind to opioid receptors. But this is not true. According to Kaplin, ketamine actually binds primarily to an entirely different set of receptors: the NMDA receptors - important for learning and memory - rather than the opioid receptors.

Normally, NMDA receptors are activated by the chemical glutamate. Turning on these receptors turns off a master control switch in the cell called mTOR, which ultimately is in charge of creating new memories. Ketamine also binds to the NMDA receptors, but it has the opposite effect in that it turns these receptors off. Turning off NMDA receptors turns on the mTOR switch, which is required for the drug's antidepressant effects.

The "ketamine as an opioid" misconception is all about mTOR. Opioid receptors in the brain are actually always turned on at low-levels, even in the absence of a drug. This low activity suppresses a chemical called cyclic AMP (cAMP). When the drug naltrexone is administered, it binds to opioid receptors, thereby increasing cAMP. Remember, ketamine turns on mTOR, which enables antidepressant effects; but if naltrexone is given in addition to ketamine, mTOR is shut down again. This is why naltrexone overrides the antidepressant effects of ketamine.

Although NMDA receptors are found together with opioid receptors in the brain, and their components can meddle with each other, this does not mean that ketamine is an opioid, says Kaplin.

In a more psychological or behavioral sense, another reason ketamine should not be considered an opioid because it actually does not have the same addictive potential as opioids. The FDA specified that ketamine is to be administered under the watch of physicians in small doses and in a controlled clinical setting to minimize any chance of abuse. The drug works much faster than traditional antidepressants, sometimes even after just one or two uses, which also decreases the risk of abuse.

Source: ScienceDaily, Medical Express

 

 

About the Author
You May Also Like
JUN 16, 2020
Microbiology
JUN 16, 2020
Dexamethasone Hailed as Effective COVID-19 Treatment
The pandemic virus SARS-CoV-2, which causes COVID-19, has killed more than 438,000 people worldwide since it emerged lat ...
JUN 23, 2020
Immunology
JUN 23, 2020
Nanosponges Mop up Viruses to Treat COVID Infections
  Scientists have developed an experimental therapy for COVID-19 that uses coated nanoparticles to intercept SARS-C ...
JUN 25, 2020
Immunology
JUN 25, 2020
The Protein That Orchestrates Cells' Dance of Death
When cells become diseased or infected, a “suicide switch” is triggered, preventing neighboring cells from b ...
JUN 23, 2020
Health & Medicine
JUN 23, 2020
New Evidence Medical Cannabis Can Lead to Decreased Opioid Use in Chronic Pain
For people with long term ongoing pain, medical cannabis is a valid option that could pave the way to reduced use of opi ...
JUN 01, 2020
Neuroscience
JUN 01, 2020
New Path to Gene Therapy for ALS
Video: Todd Cohen, PhD (UNC) discusses GA protein accumulation.  At the time of this video promising research was a ...
JUN 26, 2020
Cannabis Sciences
JUN 26, 2020
Cannabis Smoke Contains 110 Toxic Chemicals
Researchers from the University of Alberta in Canada have found that cannabis smoke contains 110 potentially toxic chemi ...
Loading Comments...